Garabedian Lab - Microbiology

Garabedian

Michael J. Garabedian, Ph.D.
Professor, Departments of Microbiology and Urology
Alexandria Center for Life Sciences – East Tower
430 East 29th Street
Office Rm. 324
Office: (212) 263-7662
Fax: (646) 501-4643
Lab: (212) 263-7968
Email: Michael.Garabedian@nyumc.org

 

 

KEY INTERESTS:

Prostate Cancer, Cardiovascular disease and diabetes, Neuronal function during stress, Nuclear Receptor function, Transcriptional regulation, Signal transduction, Peptoid-conjugated molecules for cancer therapy.
 

BIOGRAPHIC DETAILS:

Graduate Education:

PhD in Biochemistry from Brandeis University

Postdoctoral Training:

UCSF -1989-1994

Academic Appointments:

1994-Assistant Professor of Microbiology
2000- Associate Professor of Microbiology & Urology
2008-Professor of Microbiology & Urology

Major Responsibilities:

 

Genitourinary (GU) Cancer Center Program Leader; NYU Cancer Institute
Course Director; Core Foundations of Medicine (CFM)
Content Director Microbiology; Core Foundations of Medicine (CFM)
Pillar Director;  Office of Medical Education (OME)

RESEARCH INTERESTS:

Dr. Garabedian’s lab is interested in understanding the Mechanism of Nuclear Hormone Receptor Action in Cancer, Heart Disease and Neuroendocrine Function:  Specific areas of research include 1) Regulation of neuronal function by the glucocorticoid receptor (GR) in stress adaptation, 2) Role of liver X receptor (LXR) alpha in cardiovascular disease, atherosclerosis and adipocyte function in diabetes,3) Rational design approaches for targeting the androgen receptor (AR) in therapy resistant prostate cancer.
 

PUBLICATIONS:

Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
Wang Y, Dehigaspitiya DC, Levine PM, Profit AA, Haugbro M, Imberg-Kazdan K, Logan SK, Kirshenbaum K, Garabedian MJ.
Cancer Res. 2016 Sep 1;76(17):5124-32. doi: 10.1158/0008-5472.CAN-16-0385. Epub 2016 Aug 3.

Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation.
Savic D, Ramaker RC, Roberts BS, Dean EC, Burwell TC, Meadows SK, Cooper SJ, Garabedian MJ, Gertz J, Myers RM.
Genome Med. 2016 Jul 11;8(1):74. doi: 10.1186/s13073-016-0328-6.

Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression.
Wang Y, Ledet RJ, Imberg-Kazdan K, Logan SK, Garabedian MJ.
Oncotarget. 2016 Aug 2;7(31):49268-49280. doi: 10.18632/oncotarget.10284.

Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages.
Shrestha E, Hussein MA, Savas JN, Ouimet M, Barrett TJ, Leone S, Yates JR 3rd, Moore KJ, Fisher EA, Garabedian MJ.
J Biol Chem. 2016 May 20;291(21):11172-84. doi: 10.1074/jbc.M116.726729. Epub 2016 Mar 29.

miRNA Targeting of Oxysterol-Binding Protein-Like 6 Regulates Cholesterol Trafficking and Efflux.
Ouimet M, Hennessy EJ, van Solingen C, Koelwyn GJ, Hussein MA, Ramkhelawon B, Rayner KJ, Temel RE, Perisic L, Hedin U, Maegdefessel L, Garabedian MJ, Holdt LM, Teupser D, Moore KJ.
Arterioscler Thromb Vasc Biol. 2016 May;36(5):942-51. doi: 10.1161/ATVBAHA.116.307282. Epub 2016 Mar 3.

Neurotrophic-priming of glucocorticoid receptor signaling is essential for neuronal plasticity to stress and antidepressant treatment.
Arango-Lievano M, Lambert WM, Bath KG, Garabedian MJ, Chao MV, Jeanneteau F.
Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15737-42. doi: 10.1073/pnas.1509045112. Epub 2015 Nov 16.

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL.
Blood. 2015 Nov 5;126(19):2202-12. doi: 10.1182/blood-2015-04-639138. Epub 2015 Aug 31.

LXR-Mediated ABCA1 Expression and Function Are Modulated by High Glucose and PRMT2.
Hussein MA, Shrestha E, Ouimet M, Barrett TJ, Leone S, Moore KJ, Hérault Y, Fisher EA, Garabedian MJ.
PLoS One. 2015 Aug 19;10(8):e0135218. doi: 10.1371/journal.pone.0135218. eCollection 2015.

Modulation of Macrophage Gene Expression via Liver X Receptor α Serine 198 Phosphorylation.
Wu C, Hussein MA, Shrestha E, Leone S, Aiyegbo MS, Lambert WM, Pourcet B, Cardozo T, Gustafson JA, Fisher EA, Pineda-Torra I, Garabedian MJ.
Mol Cell Biol. 2015 Jun 1;35(11):2024-34. doi: 10.1128/MCB.00985-14. Epub 2015 Mar 30.

Targeting the androgen receptor with steroid conjugates.
Levine PM, Garabedian MJ, Kirshenbaum K.
J Med Chem. 2014 Oct 23;57(20):8224-37. doi: 10.1021/jm500101h. Epub 2014 Jul 8. Review.

Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.
Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X, Bourgeois W, Bitterman DS, Raetz EA, Morrison DJ, Teachey DT, Evans WE, Garabedian MJ, Carroll WL.
J Biol Chem. 2014 Jul 25;289(30):20502-15.

Brain-derived neurotrophic factor signaling rewrites the glucocorticoid transcriptome via glucocorticoid receptor phosphorylation.
Lambert WM, Xu CF, Neubert TA, Chao MV, Garabedian MJ, Jeanneteau FD.
Mol Cell Biol. 2013 Sep;33(18):3700-14. doi: 10.1128/MCB.00150-13. Epub 2013 Jul 22. Erratum in: Mol Cell Biol. 2013 Oct;33(20):4138.

Inhibition of androgen receptor and β-catenin activity in prostate cancer.
Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK.
Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15710-5. doi: 10.1073/pnas.1218168110. Epub 2013 Sep 9.

Expression of androgen receptor and its phosphorylated forms in breast cancer progression.
Ren Q, Zhang L, Ruoff R, Ha S, Wang J, Jain S, Reuter V, Gerald W, Giri DD, Melamed J, Garabedian MJ, Lee P, Logan SK.
Cancer. 2013 Jul 15;119(14):2532-40. doi: 10.1002/cncr.28092. Epub 2013 Apr 19.

A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells.
Imberg-Kazdan K, Ha S, Greenfield A, Poultney CS, Bonneau R, Logan SK, Garabedian MJ.
Genome Res. 2013 Apr;23(4):581-91. doi: 10.1101/gr.144774.112. Epub 2013 Feb 12.

Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner.
Gertz J, Reddy TE, Varley KE, Garabedian MJ, Myers RM.
Genome Res. 2012 Nov;22(11):2153-62. doi: 10.1101/gr.135681.111. Epub 2012 Sep 26.

Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK.
Oncogene. 2013 Aug 22;32(34):3992-4000. doi: 10.1038/onc.2012.412. Epub 2012 Sep 17.

Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells.
Levine PM, Lee E, Greenfield A, Bonneau R, Logan SK, Garabedian MJ, Kirshenbaum K.
ACS Chem Biol. 2012 Oct 19;7(10):1693-701. doi: 10.1021/cb300332w. Epub 2012 Aug 7.
 

LAB MEMBERS:
Elina Shrestha, PhD
Yu Wang, PhD,
Maud Voisin, PhD
Russell Ledet (graduate student co mentored with Dr. Susan Logan)
Hannah Weber (MD/PhD student)
Jeff Schneider, (MD/PhD student co mentored with Dr. Susan Logan)
Sophie Ruff (MD/PhD student co mentored with Dr. Susan Logan)
Rachel Ruoff, Lab Manager